- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Feb 23, 2022
Finance
Jeito joins NMD’s syndicate to help Danish play build clinical, U.S. strategy
The French VC attracted by NMD’s ability to identify patients with severe neuromuscular disease likely to respond to therapy
BioCentury | Dec 4, 2020
Distillery Therapeutics
Scripps team discovers RNA-targeting small molecule for myotonic and corneal dystrophies
DISEASE CATEGORY: Musculoskeletal; ophthalmic disease
INDICATION: Myotonic dystrophy type 1 (DM1); ophthalmic A Scripps Research team led by Expansion Therapeutics Inc. co-founder Matthew Disney has
INDICATION: Myotonic dystrophy type 1 (DM1); ophthalmic A Scripps Research team led by Expansion Therapeutics Inc. co-founder Matthew Disney has
BioCentury | Mar 22, 2018
Finance
NMD treats A to Z
Why INKEF, Novo Seeds participated in NMD’s €38M series
BioCentury | Jan 3, 2018
Product R&D
Expanding small molecule horizons
How 5AM newco Expansion Therapeutics is hitting RNA targets with small molecules
Items per page:
1 - 6 of 6